Healthcare has been one of the hottest sectors over the last year and continues to find new highs. The HealthCare Select Sector SPDR (XLV) was up 2.36% in the last week. That doesn't mean that every company is a good bet at any price, though. Here are four large-cap drug stocks to monitor for an entry point.

Gilead Sciences Inc. (GILD) is charging at the $100 mark, closing at $99.49 on Aug. 15. Bursting out of small consolidation that contained the stock between the end of July to mid-August, being able to break and hold above $100 will be a major test for the stock. The trend is strongly up, and since $100 is considered a psychological pivot point, it can also be used as a short-term entry point. If the current price run reaches $105 or higher, look to buy a pullback to $100 with a stop a couple dollars below and a target beyond $105. If the price falters at $100, wait to buy a pullback to trendline support near $95 to $94; a stop can be placed below $90 and if the uptrend continues look for exit above $105. (For more, see: How Gilead Sciences Became a Big Name in Biotech.)

GILD entry point

Amgen Inc. (AMGN) has been moving in a trend channel higher through most of 2013 and 2014. Its share price could to continue to run toward the top of the channel near $135, although at current levels downside risk may outweigh upside potential. That said, if the price breaks above the channel it indicates a very strong price wave, potentially reaching $145. Until proven otherwise, the channel is the main technical feature to watch. If resistance holds near the top of the channel in the $135 region, hold off on buying until the price reaches the lower portion of the channel, near $120 with a stop several dollars below. (For more, see: Channeling: Charting A Path To Success.)

AMGN entry point

Covidien plc (COV) snapped higher almost 30% in mid-June to a high of $92.68, and has since pulled back. A rally above $88 will break the short-term downward trendline, and could mean another wave higher for the stock. If that scenario plays out, the target is just below $100. Initially, the stop loss can go below $82, but if a higher swing low forms the stop can moved to just below that. Strong moves higher, such as the one seen in June, have a tendency to "fill" given enough time. When that will occur is anyone's guess, but it's possible that the price will retrace all the way back to the $75 to $73 region. If and when that occurs, it should present another good buying opportunity. (For more, see: The Stop-Loss Order: Make Sure You Use It.)

COV entry point

Unlike the three previous stocks, Zoetis, Inc. (ZTS) isn't in a long-term uptrend. Going back to early 2013, the stock has been more range bound. Since April the stock has been rallying strongly though, and has cleared resistance in the $33.35 region. It also broke a descending trendline which marks the swing highs of the range. Therefore, it could be interpreted that this stock has already broken out, in which case it has a target of $35 to $37. The stock's all-time high is $35.42, so resistance is expected in that area. If the price manages to climb there, and then falters, it's probably best to take profits instead of trying to squeeze out a larger gain. (For more, see: Pfizer Readies Zoetis For Market.)

ZTS entry point

The Bottom Line

The healthcare sector remains strong and the S&P 500 in an uptrend. Even so, that doesn't mean buying these healthcare stocks at any price is a wise play. Consider the price in the context of larger patterns, such as trend channels (when applicable) or how the waves and pullbacks of a trend are playing out. Usually buying on a pullbacks offers a better reward-to-risk ratio because a stop can be placed below a recent low; when buying on new highs a stop loss area can be harder to find. No method of analysis or trading is perfect, so ideally risk only a small amount of your account on each trade, that way even a string of losses won't significantly draw down the account. (For more, see: Range-Bound Traders—Breakout Traders—Channel Traders.)

Related Articles
  1. Stock Analysis

    How Gilead Sciences Became A Big Name In Biotech

    How does a company start with an unfortunate bout of dengue fever and grow to be a multibillion dollar corporation?
  2. Investing

    Pharmaceutical Vs. Biotech Investing: Is It Worth The Risk?

    Investopedia explains: Both pharma and biotech stocks are faced with a costly process that, when successful, can produce extremely profitable products. However, the process is unpredictable.
  3. Forex Strategies

    Two Great Currencies To Profit From Oil Volatility

    U.S. dollar crosses with Canadian and Australian dollars offer easy access to crude oil trends due to their tight correlation with energy futures.
  4. Investing

    Redefining the Stop-Loss

    Using Stop-losses for trading doesn’t mean ‘losing money’, but instead think about the money you'll start saving once you learn how they work.
  5. Mutual Funds & ETFs

    ETF Analysis: ALPS Medical Breakthroughs

    Learn more about a unique and innovative exchange-traded fund (ETF) in the biotechnology industry: the ALPS Medical Breakthroughs Fund.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares US Healthcare

    Learn about the iShares U.S. Healthcare exchange-traded fund, which invests in a wide range of health care providers, hospitals and home care facilities.
  7. Mutual Funds & ETFs

    ETF Analysis: BioShares Biotechnology Clinical Trials

    Learn more about the BioShares Biotechnology Clinical Trials Fund, a new and innovative fund focusing on breakthroughs in the health industry.
  8. Mutual Funds & ETFs

    ETF Analysis: First Trust NYSE Arca Biotech

    Learn more about the First Trust NYSE Arca Biotechnology Fund, a highly rated exchange-traded fund in the biotech space.
  9. Chart Advisor

    3 Ways to Trade the Rising Volatility

    With volatility increasing in the markets, many are turning to these three volatility-capturing exchange-traded products.
  10. Chart Advisor

    Big Double Top Patterns On the Verge of Breaking

    These stocks have created big double top chart patterns, and are on the verge of breaking the patterns to the downside--a bearish signal.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Securities-Based Lending

    The practice of making loans using securities as collateral. ...
  3. Tactical Trading

    A style of investing for the relatively short term based on anticipated ...
  4. Fintech

    Fintech is a portmanteau of financial technology that describes ...
  5. Indicator

    Indicators are statistics used to measure current conditions ...
  6. Intraday Momentum Index (IMI)

    A technical indicator that combines aspects of candlestick analysis ...
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. Tame Panic Selling with the Exhausted Selling Model

    The exhausted selling model is a pricing strategy used to identify and trade based off of the price floor of a security. ... Read Full Answer >>
  3. Point and Figure Charting Using Count Analysis

    Count analysis is a means of interpreting point and figure charts to measure vertical price movements. Technical analysts ... Read Full Answer >>
  4. What assumptions are made when conducting a t-test?

    The common assumptions made when doing a t-test include those regarding the scale of measurement, random sampling, normality ... Read Full Answer >>
  5. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  6. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!